BridgeMD
Compares treatment options for Chronic Thromboembolic Pulmonary Hypertension
Official title Switching of Sildenafil to Riociguat in CTEPH Patients
ClinicalTrials.gov ID: NCT06715280
What this study is testing
What is Riociguat (Adempas)?
Riociguat (Adempas) is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for chronic thromboembolic pulmonary hypertension.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study was designed to investigate the safety and efficacy of replacing phosphodiesterase 5 inhibitors (PDE5i) with riociguat in patients with Chronic thromboembolic pulmonary hypertension (CTEPH) who have undergone pulmonary angioplasty (BPA) and remains symptomatic despite treatments with PDE5i.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients with established diagnosis of CTEPH who are symptomatic after Balloon pulmonary angioplasty (BPA)
- Patients who are on stable maximally tolerated dose of sildenafil for at least 6 weeks as monotherapy, or in combination with other pulmonary...
- WHO functional class III at screening
- Stable dose of diuretics (if used) for at least 30 days at screening
- No recent hospitalisation due to pulmonary hypertension or heart failure for at least 30 days
You likely can't join if
- Previous treatment with riociguat other sGCs, or documented severe drug reaction or intolerance to sGCs
- Use of nitrates or nitric oxide donors (eg, nitroglycerin, amyl nitrite, isosorbide dinitrate etc) by any administration routes within 30 days of...
- Pregnant women or breast-feeding women, or women with childbearing potential not using of combination of two effective contraception methods...
- Renal impairment with glomerular filtration rate \<15mL /min
- Child-Pugh C hepatic impairment
The study team makes the final eligibility decision.
Where it's taking place
- Hong Kong, Hong Kong
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hong Kong, Hong Kong. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.